SYDNEY, MAY 2021
Dr. Parisa Asvadi Joins NeuClone as Chief Development Officer
SYDNEY, OCTOBER 2020
NeuClone Announces Positive Results from Phase I Study of Stelara® (ustekinumab) Biosimilar Candidate
SYDNEY, SEPTEMBER 2020
NeuClone Discloses Two Biosimilars Referencing Opdivo® (nivolumab) and Keytruda® (pembrolizumab)
SYDNEY, APRIL 2020
NeuClone Announces Completion of Subject Visits in Stelara® (ustekinumab) Biosimilar Phase I Clinical Trial
SYDNEY, DECEMBER 2019
NeuClone Completes Dosing in Phase I Clinical Trial of Stelara® (ustekinumab) Biosimilar Candidate
SYDNEY, DECEMBER 2019
NeuClone Announce Positive Results from Phase I Study of Herceptin® (Trastuzumab) Biosimilar Candidate
SYDNEY, OCTOBER 2019
NeuClone Announces First Human Dose of Stelara® (Ustekinumab) Biosimilar Candidate in Phase I Clinical Trial
SYDNEY, MAY 2019
NeuClone to Initiate Phase I Clinical Trial of Stelara® (Ustekinumab) Biosimilar, the Second Biosimilar from the 10-product Portfolio with Serum Institute
SYDNEY, MARCH 2019
NeuClone has completed dosing of subjects in a Phase I clinical trial with its Herceptin® (trastuzumab) biosimilar, NeuCeptin
SAN FRANCISCO, JANUARY 2019
NeuClone representatives attend the 37th Annual J.P. Morgan Healthcare Conference
SYDNEY, JANUARY 2019
NeuClone features in BioWorld: Interview with Dr Noelle Sunstrom
SYDNEY, DECEMBER 2018
NeuClone Announces its Sixth Biosimilar Candidate Perjeta® (Pertuzumab) for Use in Combination Therapy with Herceptin® (Trastuzumab)